BleedToProfit retweeted
Sk Hynix is now trading under $SKHYV!
It's now up an insane 16%.
I wonder how Sk Hynix over in Korea is going to react on Monday.
BleedToProfit retweeted
Micron up 7% they just doubled down on AI.
$MU broke ground on a $9.3B AI memory facility in Japan, backed by up to $3.1B in government support.
The plant will produce next-generation HBM chips starting in 2028
BleedToProfit retweeted
Semianalysis said $NVDA Kyber NVL144 rack architecture has been delayed more than 12 months to 2028 due to manufacturability issues.
The planned NVL72x2 back-to-back rack was also cancelled after pushback from major cloud providers.
They think this is bullish for $AMD MI series and $GOOGL TPUs as Rubin Ultra now has fewer scale-up options.
$GRASS users look this way if you are getting peanuts 😔
join.honeygain.com/TRIGEA1D3…
BleedToProfit retweeted
$NBIS is expanding into Spain securing an 18MW lease with Merlin Properties at its Getafe campus.
The move marks Nebius first entry into the Spanish market and another step in scaling its European AI infrastructure footprint.
BleedToProfit retweeted
Congrats to $SIVE, they have now raised an upside round of 700m SEK from institutional investors.
The round was “Multiple Times Oversubscribed” and slightly upsided.
Validating immense institutional demand around current market prices.
This raise was specifically for "expanding manufacturing capacity for InP lasers and optical amplifiers" (volume ramping with fab-light model).
Hinting Sivers has reached the inflection point for scale.
The round was at 57 SEK (current prices are 63 SEK), which I’m personally very happy about as it’s around current market prices, which typically sets a floor.
Instituional money has now de-risked the balance sheet, and funded Sivers transition to HVM.
Great news with a Direct share issue that was oversubscribed multiple time.
What started as a planned SEK 600M (+$61m) raise was upsized to SEK 700M ($73m) thanks to strong institutional investor demand. That's a clear vote of confidence in $SIVE and the ramping within AI photonics, SATCOM and defense.
SEK 700M is roughly US$73M in fresh capital, providing even greater financial flexibility to accelerate execution and scale the business.
Strong demand. Strong balance sheet. Exciting times ahead.
Great work by the Sivers team! Congratulations!
$SIVE #AI #Photonics
sivers-semiconductors.com/pr…
BleedToProfit retweeted
$SIVE CEO comments on US listing:
"We continue to invest and make progress on all necessary steps with the intent to complete the listing process over the next few quarters”.
Looks like US listing will happen in H1'27 (or Q4'26, minimum).
AI continues to reshape industries across the globe. While large-cap names lead the headlines, smaller opportunities such as $XMAX deserve a closer look.
166
BleedToProfit retweeted
How to SPOT Sector Rotation EARLY
ETF’s will tell you when to Buy or Sell BEFORE the move happens
Top AI super cycle ETF’s by sector:
Semis | $SMH
$NVDA $AMD $AVGO $INTC
Memory | $DRAM
$MU $SNDK $WDC
Photonics | $EUV
$TSM $MRVL $COHR
Software | $IGV
$PLTR $ORCL $NOW $MSFT
Healthcare | $IHF
$HIMS $UNH $CVS
Cybersecurity | $CIBR
$PANW $CRWD $FTNT $ZS
HPC | $WGMI
$IREN $CORZ $MARA $RIOT $HUT
Robotics | $BOTZ
$TSLA $ISRG $SYM
Space / Defense Innovation | $ARKX
$RKLB $KTOS $AVAV
Nuclear | $NLR
$OKLO $CCJ $CEG $SMR
Quantum | $QTUM
$IONQ $RGTI $QBTS
BleedToProfit retweeted
$SIVE dip being slightly bought up at open? Can we even trust this?
BleedToProfit retweeted
Chinese AI model maker Zhipu is considering raising several billion dollars in Hong Kong as soon as next month, per Bloomberg.
Six-month IPO lockup expires July 8.
Zhipu raised $558M in its January Hong Kong IPO at HK$116.20/share. The stock traded as high as HK$2,980 this week, giving the company a market value above HK$1T, or ~$128B.
The company also aims to issue shares in Shanghai to fund AI model development.
Bloomberg says talks are ongoing and may not lead to a deal, with concerns still around profitability and competition against rivals like Anthropic.
BleedToProfit retweeted
$TSM TSMC is reportedly raising foundry prices by 5-10% across advanced nodes 7nm and below.
The increases could impact roughly 75% of the company’s wafer revenue and signal continued strong AI-driven demand.
BleedToProfit retweeted
$OSCR Path to Recovery and Leading Indicators to Watch Ahead
As OSCR is closing in on a 52 week high, its been a painful ride so far and the question has always been are finally out of the consolidation phase and out of the subsidy overhang and unexpected market morbidity that messed up the sector in H2 last year.
I was trying to reconcile and see see how the path might look like for OSCR for rest of 2026, I want to provide a quick glance on what happened, what OSCR did to navigate this and what are the leading indicators that we can observe to see if we are finally out consolidation and overhang to realize the true value of business and valuation it deserves.
1) What Happened in the Broader Health Insurance Industry (Especially for Oscar) in H2 2025
After the big Medicaid redeterminations wrapped up in 2024, a lot of healthier folks dropped coverage or stayed out of the ACA individual market, while higher-acuity people shifted in from Medicaid. That messed up the risk pools across the industry.For Oscar it hit pretty hard in the back half of the year:Q2 2025 MLR jumped to 91.1% (from 79.0% the year before).
Net risk adjustment payable shot up by $316 million.
Full-year 2025 MLR came in at 87.4% (vs 81.7% in 2024).
Ended up with an operating loss of $396.4 million even though revenue grew to $11.7 billion.
Pretty much the whole industry saw higher MLRs and bigger risk adjustment outflows because of the worsening morbidity.
2) What the 2025 Wakely Report Said
Wakely’s July 2025 “2025 Individual Market Risk Pool Considerations” (plus the later updates) laid it out clearly. Demographic-normalized relative risk scores rose more than 8% compared to 2023/2024 levels, with jumps as high as 11.6% in non-expansion FFE states. They tied it straight back to the Medicaid redetermination inflows. That report basically confirmed exactly why everyone, including Oscar, was seeing the MLR pressure in the second half of 2025.
3) What $OSCR Did to Navigate It
Oscar didn’t just sit there. They resubmitted 2026 rate filings in states covering ~98% of their membership to properly account for the higher market risk scores. They doubled down on disciplined pricing, pushed more affordable Bronze options, leaned on their broker tools and tech platform for retention and acquisition, and kept tight control on utilization and costs. Solid moves that set them up much better heading into 2026.
4) Recent Conference Call: Favorable Early Signs and Waiting on Wakely
Management said the market contraction is tracking in line to favorable versus their 20–30% estimate, and claims plus third-party data are showing market morbidity in line to favorable with their pricing. They’re being conservative on risk adjustment accruals (~24% of premiums vs a ~20% full-year target) and specifically mentioned waiting for more Wakely clarity.Q1 2026 results looked strong:Revenue up 53% YoY to about $4.6 billion.
MLR improved big-time to 70.5% (490 bps better YoY), helped by pricing, the Bronze/new-member seasonality, and $68 million in favorable prior-period development.
5) Leading indicators to watch for
The upcoming 2026 Wakely report on enrollment, payments, and morbidity trends is the big one to watch. If it confirms stable or lighter-than-feared market morbidity, better risk adjustment dynamics, and member mix that lines up with Oscar’s assumptions, it should de-risk the year and open the door to upside.
Oscar has reaffirmed full-year 2026 guidance: Revenue $18.7–19.0 billion, MLR 82.4–83.4%, and operating earnings $250–450 million. Tailwinds from continued membership/share gains in a smaller but stabilizing market, already-baked rate increases, normalizing risk adjustment, and SG&A leverage should help drive that.
As I compile this post, I was reminded of the below reply from @mtbert to one of the questions around the earnings call, when mark was replying to puzzles which shows, why they are able to navigate this better than what all the analysts could think off.
@investingwithac @obfuscated_id @degeninvestor7 @Couch_Investor @TheRonnieVShow @dannycheng2022 @sheslee would love to hear your thoughts as I try out my first shot at long post, hope to keep sharing more !!
BleedToProfit retweeted
Claude reliability stats look quite bad, to be honest.
Think Anthropic probably needs $NBIS more than Nebius needs Anthropic.
It would make a lot of sense for them to agree on a wider partnership where Nebius doesn't just rent them compute, which they clearly can't utilize in a great way yet, but helps them build and operate their own AI cloud.
Most people still take Nebius' bulletproof AI cloud reliability for granted (second picture).
It is actually incredibly hard.
And Nebius might want to consider monetizing it across AI infrastructure via a Palantir-like AIP service for cloud operations.
Anthropic would be such a perfect billboard.
(Not investment advice. I am not implying a Nebius x Anthropic deal. This is purely my own analytical speculation.)
BleedToProfit retweeted
$QBTS --- The U.S. President has signed two brand-new executive orders designed to accelerate federal government procurement and real-world deployment of quantum computing, while mandating full migration to Post-Quantum Cryptography (PQC) by the 2030–2031 window. This policy instantly redefines quantum tech from a long-term academic theoretical pursuit into near-term federal budget procurement planning, delivering direct tailwinds for domestic supplier $QBTS.
$QBTS recently closed its acquisition of Quantum Circuits, Inc. Leveraging its proprietary dual-rail qubit technology, D-Wave has validated that its existing cryogenic control chips can operate gate-model qubits with zero fidelity loss. During its early-June NYSE Investor Day, management laid out an ambitious product roadmap: the firm targets launching a fault-tolerant gate-model system housing 175 physical qubits by 2028.
1. The Only Pragmatic Commercial Pure-Play Quantum Name
While most industry peers remain confined to lab trials struggling to stabilize small qubit arrays, D-Wave’s Advantage2™ quantum annealing systems are already solving large-scale real-world optimization use cases across logistics scheduling, financial portfolio optimization, and defense missile defense planning via partnerships with Anduril and Davidson. In a recent blockchain testnet benchmark, D-Wave’s QPU outperformed traditional CPU-GPU hybrid stacks on mining and node computational throughput.
2. Massively Strengthened Cash Runway Buffer
As of the end of Q1 2026, the company’s cash reserves hit $588 million, representing a 93% year-over-year increase. For early-stage deep tech growth equities, robust liquidity eliminates the need for frequent dilutive secondary offerings over the next 3–4 years to sustain operations, removing the single largest overhang suppressing its valuation.
3. Wall Street Institutional Re-Rating Underway
Top sell-side banks including Mizuho have lifted their ratings and price targets in recent weeks, with Wall Street’s consensus rating now a unanimous Strong Buy. Analysts argue the market has undervalued its massive forward order pipeline due to historical quarterly revenue volatility.
The next phase of the AI trade may not be limited to established names. Companies like $XMAX could attract more attention if they execute successfully.
132







































